Abstract | BACKGROUND: METHODS: Sera from 33 HDV- RNA-positive patients from the international HIDIT-1 trial were available for anti-HDV IgM testing (ETI-DELTA-IGMK-2 assay, DiaSorin, Saluggia, Italy) before therapy, at treatment weeks 24 and 48, and at 24 weeks after the end of treatment. RESULTS: Anti-HDV IgM tested positive in 31 out of the 33 patients (94%) prior to treatment. HDV IgM levels correlated with histological inflammatory activity (r=0.51, P<0.01) and were higher in patients with alanine aminotransferase and γ- glutamyl transpeptidase levels above the median (P<0.05). Quantitative anti-HDV IgM values declined in patients responding to antiviral therapy, however anti-HDV IgM remained positive after treatment in the majority of virological responders. CONCLUSIONS: We suggest that anti-HDV IgM testing might give additional useful information to determine disease activity in hepatitis delta and to predict treatment response to antiviral therapy with type I interferons. However, determination of anti-HDV IgM can not substitute HDV RNA testing, which remains the primary virological marker for response to therapy.
|
Authors | Ingmar Mederacke, Cihan Yurdaydin, George N Dalekos, Birgit Bremer, Andreas Erhardt, Yilmaz Cakaloglu, Kendal Yalcin, Selim Gurel, Stefan Zeuzem, Kalliopi Zachou, Hakan Bozkaya, Hans Peter Dienes, Michael P Manns, Heiner Wedemeyer, Hep-Net/International Delta Hepatitis Study Group |
Journal | Antiviral therapy
(Antivir Ther)
Vol. 17
Issue 2
Pg. 305-12
( 2012)
ISSN: 2040-2058 [Electronic] England |
PMID | 22293066
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- Hepatitis Antibodies
- Immunoglobulin M
- Interferon-alpha
- Organophosphonates
- RNA, Viral
- Recombinant Proteins
- Polyethylene Glycols
- adefovir
- gamma-Glutamyltransferase
- Alanine Transaminase
- Adenine
- peginterferon alfa-2a
|
Topics |
- Adenine
(analogs & derivatives, therapeutic use)
- Adult
- Alanine Transaminase
(blood)
- Antiviral Agents
(therapeutic use)
- Female
- Hepatitis Antibodies
(blood)
- Hepatitis D
(drug therapy, immunology)
- Hepatitis Delta Virus
(genetics, immunology)
- Humans
- Immunoglobulin M
(blood, immunology)
- Interferon-alpha
(therapeutic use)
- Male
- Middle Aged
- Organophosphonates
(therapeutic use)
- Polyethylene Glycols
(therapeutic use)
- RNA, Viral
(blood)
- Recombinant Proteins
(therapeutic use)
- Young Adult
- gamma-Glutamyltransferase
(blood)
|